SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: idahoranch1 who wrote (38507)1/7/2017 2:08:24 PM
From: dorightbythem  Read Replies (1) of 63291
 
Another reason added to the argument that the Company will be gobbled up prior to being a 10 bagger if they receive AA.

Article's Telling Numbers :

" Despite the lower number of approvals, The FDA’s Novel Drugs Summary for 2016 notes that the approved drugs have the potential to have a big impact in several areas. Eight of the drugs approved last year were identified as first-in class treatments, including multiple sclerosis drug Zinbryta, and nine (41%) of the novel drugs were approved as treatments for rare diseases that affect fewer than 200,000 Americans. Many of the drugs were approved in one or more of the agency’s expedited categories, with 73% of them receiving Fast Track, Breakthrough, Priority Review and/or Accelerated Approval status. "
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News